Telaglenastat

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Telaglenastat
Accession Number
DB15232
Description

Telaglenastat is under investigation in clinical trial NCT02071862 (Study of the Glutaminase Inhibitor CB-839 in Solid Tumors).

Type
Small Molecule
Groups
Investigational
Structure
Thumb
Weight
Average: 571.58
Monoisotopic: 571.161343324
Chemical Formula
C26H24F3N7O3S
Synonyms
Not Available
External IDs
  • CB-839

Pharmacology

Indication
Not Available
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Products

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as phenylacetamides. These are amide derivatives of phenylacetic acids.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Phenylacetamides
Direct Parent
Phenylacetamides
Alternative Parents
Phenoxy compounds / Phenol ethers / N-arylamides / Pyridines and derivatives / Pyridazines and derivatives / Imidolactams / Thiadiazoles / Heteroaromatic compounds / Trihalomethanes / Secondary carboxylic acid amides
show 6 more
Substituents
Alkyl fluoride / Alkyl halide / Aromatic heteromonocyclic compound / Azacycle / Azole / Carbonyl group / Carboxamide group / Carboxylic acid derivative / Halomethane / Heteroaromatic compound
show 19 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available

Chemical Identifiers

UNII
U6CL98GLP4
CAS number
1439399-58-2
InChI Key
PRAAPINBUWJLGA-UHFFFAOYSA-N
InChI
InChI=1S/C26H24F3N7O3S/c27-26(28,29)39-20-9-5-6-17(14-20)15-22(37)31-21-12-11-18(33-34-21)7-1-2-10-24-35-36-25(40-24)32-23(38)16-19-8-3-4-13-30-19/h3-6,8-9,11-14H,1-2,7,10,15-16H2,(H,31,34,37)(H,32,36,38)
IUPAC Name
N-[6-(4-{5-[2-(pyridin-2-yl)acetamido]-1,3,4-thiadiazol-2-yl}butyl)pyridazin-3-yl]-2-[3-(trifluoromethoxy)phenyl]acetamide
SMILES
FC(F)(F)OC1=CC(CC(=O)NC2=NN=C(CCCCC3=NN=C(NC(=O)CC4=NC=CC=C4)S3)C=C2)=CC=C1

References

General References
Not Available
ChemSpider
34959639
BindingDB
109086
ChEMBL
CHEMBL3639788
ZINC
ZINC000169698697

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2Active Not RecruitingTreatmentAdvanced Renal Cell Carcinoma / Metastatic Renal Cell Carcinoma1
2Active Not RecruitingTreatmentClear Cell Renal Cell Carcinoma1
2CompletedTreatmentTNBC - Triple-Negative Breast Cancer / Triple Negative Breast Cancer (TNBC)1
2RecruitingTreatmentAdvanced Malignant Solid Neoplasm / Metastatic Malignant Solid Neoplasm / NF1 Mutation Positive Malignant Peripheral Nerve Sheath Tumor / Unresectable Malignant Solid Neoplasm1
2RecruitingTreatmentKEAP1 Gene Mutation / NFE2L2 Gene Mutation / Non-Small Cell Lung Carcinoma (NSCLC) / Non-Squamous Non-Small Cell Lung Cancer / Non-Squamous Non-Small Cell Neoplasm of Lung / Non-Squamous Non-Small-Cell Lung Cancer / NRF2 Gene Mutation1
1CompletedTreatmentAcute Lymphocytic Leukemia (ALL) / Acute Myeloid Leukemia (AML)1
1CompletedTreatmentDiffuse Large B-Cell Lymphoma (DLBCL) / Multiple Myeloma (MM) / Non-Hodgkin's Lymphoma (NHL) / Other B-cell NHL Subtypes, Including WM / T-cell NHL / Waldenström's Macroglobulinemia (WM)1
1CompletedTreatmentFumarate Hydratase (FH)-Deficient Tumors / Mesothelioma / Non-Small Cell Lung Carcinoma (NSCLC) / Renal Cell Adenocarcinoma / Succinate Dehydrogenase (SDH)-Deficient Gastrointestinal Stromal Tumors (GIST) / Succinate Dehydrogenase (SDH)-Deficient Non-gastrointestinal Stromal Tumors / Triple Negative Breast Cancer (TNBC) / Triple-Negative Breast Cancer (TNBC) / Tumors Harboring Amplifications in the cMyc Gene / Tumors Harboring Isocitrate Dehydrogenase-1 (IDH1) and IDH2 Mutations / Tumors, Solid1
1CompletedTreatmentHealthy Volunteers1
1Not Yet RecruitingTreatmentOvarian Cancer / Resistant BRCA Wild-Type Ovarian Cancer1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00151 mg/mLALOGPS
logP3.73ALOGPS
logP4.74ChemAxon
logS-5.6ALOGPS
pKa (Strongest Acidic)6.94ChemAxon
pKa (Strongest Basic)4.33ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count8ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area131.88 Å2ChemAxon
Rotatable Bond Count13ChemAxon
Refractivity141.14 m3·mol-1ChemAxon
Polarizability55.53 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Drug created on May 20, 2019 09:02 / Updated on June 12, 2020 10:53

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates